CIBC Asset Management’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-6,040
Closed -$1.48M 1306
2022
Q3
$1.48M Buy
6,040
+525
+10% +$142K 0.01% 603
2022
Q2
$1.36M Buy
5,515
+1,198
+28% +$323K 0.01% 603
2022
Q1
$1.43M Buy
4,317
+44
+1% +$13.5K 0.01% 626
2021
Q4
$1.53M Buy
4,273
+237
+6% +$80.1K 0.01% 601
2021
Q3
$1.31M Buy
4,036
+126
+3% +$42.7K 0.01% 616
2021
Q2
$1.22M Buy
3,910
+43
+1% +$13.2K ﹤0.01% 633
2021
Q1
$1.23M Sell
3,867
-79
-2% -$25.3K 0.01% 614
2020
Q4
$1.28M Hold
3,946
0.01% 581
2020
Q3
$1.09M Buy
3,946
+75
+2% +$21.6K 0.01% 565
2020
Q2
$935K Buy
3,871
+64
+2% +$12.9K 0.01% 579
2020
Q1
$553K Sell
3,807
-297
-7% -$49.3K ﹤0.01% 613
2019
Q4
$700K Buy
4,104
+61
+2% +$11.3K ﹤0.01% 666
2019
Q3
$719K Sell
4,043
-50
-1% -$10.8K ﹤0.01% 658
2019
Q2
$1.07M Buy
4,093
+85
+2% +$22.6K 0.01% 587
2019
Q1
$1.15M Buy
4,008
+156
+4% +$51.8K 0.01% 571
2018
Q4
$1.25M Sell
3,852
-4
-0.1% -$1.39K 0.01% 491
2018
Q3
$1.73M Buy
3,856
+150
+4% +$59.1K 0.01% 461
2018
Q2
$1.52M Buy
3,706
+2,238
+152% +$811K 0.01% 489
2018
Q1
$427K Hold
1,468
﹤0.01% 744
2017
Q4
$275K Hold
1,468
﹤0.01% 845
2017
Q3
$248K Buy
+1,468
New +$222K ﹤0.01% 870

Other funds holding ABMD

CIBC Asset Management's ABMD Position: Q4 2022 in Review

CIBC Asset Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 6,040 shares — an estimated $1.48M sold.

CIBC Asset Management first reported a position in ABMD in Q3 2017 and held it in 21 quarters. The position peaked at $1.73M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • CIBC Asset Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • CIBC Asset Management sold 6,040 Abiomed Inc shares in Q4 2022, an estimated $1.48M.
  • CIBC Asset Management first reported a position in Abiomed Inc in Q3 2017 and held it in 21 quarters.
  • CIBC Asset Management's Abiomed Inc position peaked at $1.73M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on CIBC Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.